Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists
Ludovico Arcuri(University of Ferrara), Michele Morari(University of Padua)
Cited by 22
Related Papers
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472
[Nphe<sup>1</sup>,Arg<sup>14</sup>,Lys<sup>15</sup>]Nociceptin‐NH<sub>2</sub>, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
|British Journal of Pharmacology|2002|163
Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol]: In Vitro Studies
|Journal of Pharmacology and Experimental Therapeutics|2007|97
Modulation of 5‐hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin
|British Journal of Pharmacology|2000|72
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortex
|British Journal of Pharmacology|2003|62